Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

IP: Rafael Simó Canonge
Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Patricia Bogdanov Baruj, Andreea Ciudin Mihai, Ferran Casals Riera, Itziar Busquets Saez, Maddalen Zufiaurre Seijo, Enrique Franky Vargas, José Raul Herance Camacho, Ingrid Balcells Ortega, Marco Inzitari
Funding agency: EUROPEAN COMMISSION
Funding: 974782.7
Reference: RECOGNISED_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

"Estudi de la suceptibilitat genètica com a predictor de la pèrdua de pes i la resolució de les comorbiditats associades a l'obesitat després de cirurgía bariàtrica"

IP: Rafael Simó Canonge
Collaborators: Gemma Cuberas Borros
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 32160
Reference: SLT002/16/00497
Duration: 01/01/2017 - 31/12/2019

Grups de recerca en Diabetis i Metabolisme

IP: Rafael Simó Canonge
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 20000
Reference: 2017SGR01144
Duration: 12/04/2019 - 30/09/2021

Administración tópica de agonistas del receptor de GLP-1: una nueva estrategia para el tratamiento de la retinopatía deiabética

IP: Rafael Simó Canonge
Collaborators: Patricia Bogdanov Baruj
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 266200
Reference: SAF2016-77784-R
Duration: 30/12/2016 - 29/12/2019

Related news

The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.

The study evaluates elecoglipron and shows improvements in glycemic control and body weight compared with placebo.

The study is expected to contribute to the identification of new therapeutic targets and the development of nutritional strategies to improve health.

Related professionals

Pablo Palaín Poncelas

Pablo Palaín Poncelas

Tècnic de recerca
Digital Transformation Directorate
Read more
Cristina Márquez González

Cristina Márquez González

Research technician
Stroke research
Read more
Fernando Sampedro Picon

Fernando Sampedro Picon

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Laia Cujó Beca

Laia Cujó Beca

Research assistant
Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.